| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 468 |
| Gender | Both Genders |
| Age Range | 0-1 |
| Body Types | Average |
Administration of _l. reuteri_ DSM 17938 to infants during the first three months of life greatly reduced the occurrence of infantile colic relative to placebo, and also improve gastrointestinal symptoms such as increasing bowel evacuations (reducing risk of constipation) and regurgitations.
Ultimately, prophylactic treatment of infants with DSM 17938 resulted in less pediatric department visits and was estimated to save both parent and community over $200 (USD).
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 44 |
| Gender | Both Genders |
| Age Range | 0-1 |
_L. reuteri_ DSM 17938 (10^8^ CFU) in infants who are at least six months old but suffering from constipation noted that supplementation was able to increase bowel frequency at all tested time points (2, 4, and 8 weeks) relative to placebo treatment; stool consistency appeared to soften over the course of the 8 weeks of supplementation, but the softening was not significantly different than placebo.
The instances of inconsolable crying during this time did not differ between groups as both increased over the study period.